IdentifAI Genetics
Tel Aviv, Israel· Est.
A next‑generation NIPT platform that digitally isolates fetal DNA for comprehensive, early prenatal genetic screening.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $12M
AI Company Overview
A next‑generation NIPT platform that digitally isolates fetal DNA for comprehensive, early prenatal genetic screening.
Prenatal genetics
Technology Platform
Proprietary bioinformatics pipeline that digitally isolates fetal cfDNA from maternal blood, reconstructs the fetal genome at high resolution, and detects point mutations and chromosomal anomalies.
Opportunities
Expansion into global markets and broader HMO partnerships; leveraging the platform to add post‑natal and carrier screening applications.
Risk Factors
Regulatory approval timelines, reimbursement challenges, and competition from established NIPT providers with larger commercial footprints.
Competitive Landscape
Competes with Illumina, Natera, Roche, and BGI; Differenti by by its ability to detect point mutations and chromosomal anomalies in a single non‑invasive test.